
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical is a clinical-stage oncology therapeutics company with a promising and unique technology, Alpha DaRT, which utilizes alpha particles for localized radiation therapy. The company has a strong pipeline targeting different tumor types and has multiple ongoing clinical trials in the U.S., which could potentially lead to commercial success. Its strong cash position and potential approval in Japan add to the positive outlook for the company. However, risks such as failure in clinical trials and competition should be considered.
Bears say
Alpha Tau Medical is showing promise in its innovative Alpha DaRT technology for treating various types of cancers. However, the company's reliance on a single product and limited revenue sources from only a few countries may pose significant financial risks. Additionally, the FDA's Breakthrough Device designation for Alpha DaRT is not a guarantee of regulatory approval, and the modular PMA submission process could lead to delays and uncertainties, further adding to the company's potential risks.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares